|
- Biologicals - World Health Organization (WHO)
Biologicals are a class of medicines made from living cells taken from plants, animals or bacteria These cells are use in creating many types of health care products, including vaccines This group of medicines also includes products derived from human blood and plasma for the treatment of many life-threatening diseases and for surgical procedures
- Biosimilars: expanding access to essential biologic therapies
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, auto-immune diseases, and diabetes These therapies can offer significant benefits in efficacy, safety, and convenience, compared to conventional medicines However, their high costs have limited accessibility for many patients globally Biosimilar versions of biologic medicines
- Call for applications closed - 2025 Introductory course for biologics . . .
Call for applications closed - 2025 Introductory course for biologics development and manufacturing organised by the Global Training Hub for Biomanufacturing (GTH-B) in Seoul, Republic of Korea Deadline for applications: 07 March 2025 18:00 (KST)
- Guidelines for Biologicals - World Health Organization (WHO)
Guidelines for the production and control of inactivated oral cholera vaccine, Annex 3, TRS No 924 Guidelines for the production and control of inactivated oral
- Biotherapeutic products - World Health Organization (WHO)
A major industrial application of biotechnology is in the development and preparation of biological medicinal products using genetically engineered bacteria, yeast, fungi, cells or even whole animals and plants
- Call for applications - 2026 Introductory course for Biologics . . .
The course includes pre-clinical clinical trials, biologics manufacturing processes, quality control assessment, and regulatory affairs to develop and produce vaccines and biologics, among others
- WHO good manufacturing practices for biological products
Good manufacturing practices (GMP) for biological products were first published by WHO in 1992 (1) This current revision reflects subsequent developments that have taken place in science and technology, and in the application of risk-based approaches to GMP (2–14) The content of this document should be considered complementary to the general recommendations set out in the current WHO good
- Monoclonal antibodies - World Health Organization (WHO)
Monoclonal antibodies (mAbs) are immunoglobulins derived from a monoclonal cell line and which have a defined specificity
|
|
|